# REC-1245

Source: https://onco.cc/drugs/rec-1245/  
OnCo record `rec-1245` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

REC-1245 is an experimental protein degrader from Recursion Pharmaceuticals, in phase 1 trials for solid tumours and lymphoma.

## Summary

REC-1245 is a protein degrader (small molecule) from Recursion Pharmaceuticals. A highly potent RBM39 degrader; the company describes RBM39 as a DNA damage response target whose loss mimics CDK12 loss. Its furthest stage is phase 1, for solid tumours and lymphoma. ClinicalTrials.gov registers it in one study linked below. Pipeline page: 'Status: Phase 1'; phase 1 DAHLIA study ongoing. Registry NCT06678659 (phase 1/2) recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: REC-1245
- Modality: Protein degrader (small molecule)
- Mechanism: A highly potent RBM39 degrader; the company describes RBM39 as a DNA damage response target whose loss mimics CDK12 loss.

## Sources

- Recursion Pharmaceuticals: recursion.com: https://www.recursion.com/pipeline
- Recursion Pharmaceuticals: recursion.com: https://www.recursion.com/pipeline
- ClinicalTrials.gov: trials of REC-1245: https://clinicaltrials.gov/search?intr=REC-1245

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- targets: [RBM39](https://onco.cc/targets/rbm39/)
- companies: [Recursion Pharmaceuticals](https://onco.cc/companies/recursion/)
- trials: [A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer](https://onco.cc/trials/nct06678659/)

---
JSON: https://onco.cc/api/v1/entities/rec-1245.json